|
1
|
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
|
J Clin Oncol
|
2006
|
2.81
|
|
2
|
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).
|
BMJ
|
2012
|
2.44
|
|
3
|
High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
|
J Med Genet
|
2013
|
1.50
|
|
4
|
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
|
Breast Cancer Res
|
2011
|
1.22
|
|
5
|
Patients' characteristics and rate of Internet use to obtain cancer information.
|
J Public Health (Oxf)
|
2006
|
1.08
|
|
6
|
Estimating cancer risks from a retrospective cohort of patients with MMR gene mutations.
|
J Clin Oncol
|
2013
|
1.06
|
|
7
|
Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.
|
Eur J Cancer
|
2006
|
0.97
|
|
8
|
Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics.
|
Genet Med
|
2010
|
0.92
|
|
9
|
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
|
Int J Cancer
|
2005
|
0.91
|
|
10
|
Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO).
|
Breast Cancer Res Treat
|
2011
|
0.90
|
|
11
|
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
|
Breast Cancer Res Treat
|
2008
|
0.90
|
|
12
|
Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
|
Eur J Hum Genet
|
2011
|
0.89
|
|
13
|
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.
|
Oncogene
|
2002
|
0.89
|
|
14
|
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.86
|
|
15
|
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).
|
Breast Cancer Res
|
2012
|
0.85
|
|
16
|
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
|
Fam Cancer
|
2004
|
0.83
|
|
17
|
Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
0.83
|
|
18
|
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.
|
Breast Cancer Res
|
2010
|
0.82
|
|
19
|
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
|
Fam Cancer
|
2012
|
0.82
|
|
20
|
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
|
Br J Cancer
|
2008
|
0.81
|
|
21
|
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.79
|
|
22
|
Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
|
Psychooncology
|
2013
|
0.78
|